Mature Erythrocyte Surface Coupling for Reduced Cell-Therapy Complexity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cell engineering methods for cancer immunotherapy, such as CAR-T, are complex, costly, and pose safety concerns, while direct immune cell activation strategies like 4-1BB stimulation risk systemic adverse reactions, and immune cells have short half-lives and are inhibited by tumor microenvironments.
Innovation Solution
A method is developed to covalently couple therapeutic molecules or biomacromolecules, such as antibodies, to the surface of mature red blood cells using GDP-fucose derivatives and fucosyltransferase, creating engineered erythroid cells that can activate NK cells and CD8+ T cells in vivo, avoiding the need for in vitro amplification and customization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CAR-T cell engineering method is used to recognize and kill tumor cells, then therapeutic effect is improved, but technical complexity and cost increase significantly
Solution Approach 1:
The patent uses red blood cells as intermediary carriers to deliver 4-1BB activating antibodies to the tumor microenvironment. Instead of directly engineering T cells with complex CAR structures, the invention employs a simpler RBC-based delivery system that indirectly activates endogenous immune cells, thereby reducing technical complexity while maintaining therapeutic efficacy
Solution Approach 2:
The patent couples therapeutic antibodies to red blood cell surfaces, creating a simplified version of cell therapy that mimics the function of engineered immune cells without requiring complex genetic modification. This 'copy' approach uses off-the-shelf RBCs as vehicles to deliver activating signals, avoiding the need for sophisticated CAR-T manufacturing processes
2Adaptability or versatility
If viral transduction is used to introduce CAR genes, then new properties are provided to engineered cells, but safety concerns arise from inconsistent reproducibility and heterogeneous expression
Solution Approach 1:
The patent employs red blood cells as disposable, short-lived carriers that naturally circulate and deliver therapeutic payloads without requiring long-term persistence or complex engineering. These RBC-based carriers are inexpensive, easily produced at scale, and their temporary presence in the body avoids many safety issues associated with permanent genetic modification
Solution Approach 2:
The patent leverages the natural properties of red blood cells and their ability to spontaneously interact with immune cells in the tumor microenvironment. The system uses endogenous metabolic pathways and natural cell-cell interactions to achieve therapeutic effects without requiring complex external control mechanisms or sophisticated gene delivery systems
3Quantity of substance
If immune cells are amplified in vitro and transferred back to patient, then quantity of NK and T cells is increased, but operation cost and time increase
Solution Approach 1:
The patent performs preliminary action by pre-coupling 4-1BB activating antibodies to red blood cell surfaces before administration. This preparation step allows the therapeutic agents to be ready for immediate use upon injection, eliminating the need for time-consuming in vitro amplification and customization of immune cells while ensuring adequate quantity of active therapeutic complexes
Solution Approach 2:
The patent creates a universal RBC-based delivery platform that can be used for multiple therapeutic applications without requiring patient-specific customization. The same RBC coupling methodology can deliver different therapeutic molecules for various indications, dramatically reducing operational time and cost compared to personalized cell therapy approaches
4Reliability
If 4-1BB stimulation is used to activate immune cells, then immune cell activation is achieved, but systemic adverse reactions occur
Solution Approach 1:
The patent applies local quality by targeting 4-1BB activation specifically to the tumor microenvironment rather than systemically. Red blood cells carrying 4-1BB antibodies accumulate at tumor sites through the enhanced permeability and retention effect and specific homing mechanisms, delivering activating signals locally to immune cells infiltrating the tumor while minimizing exposure and adverse reactions in healthy tissues
Solution Approach 2:
The patent uses red blood cells as intermediaries to deliver 4-1BB activating antibodies to the tumor microenvironment. This indirect delivery approach allows controlled local activation of immune cells without direct systemic administration of high doses of activating agents, thereby reducing systemic adverse reactions while maintaining effective local immune stimulation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered red blood cells provide sustained activation of immune cells, effectively stimulating NK cells and CD8+ T cells, reducing tumor burden with a safer and more accessible treatment approach.
Implementation Method 1
Glycosylation is a process of covalently linking carbohydrates and target molecules (usually proteins and lipids). Protein glycosylation, being an enzymatic reaction in the absence of a template, is carried out by a donor molecule, usually an activated nucleotide sugar, targeting the site (hydroxyl or other functional groups) of a receptor and conducing a specific glycoconjugate reaction under the action of glycosyltransferases.
Implementation Method 2
Fucosyltransferase is an enzyme that transfers L-fucose from GDP-fucose (guanosine diphosphate fucose) donor substrates to receptor substrates. Fucosyltransferase catalyzes the transfer of fucoside to the N-polysaccharide of mammalian glycoprotein.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Disclosed in the present invention is a method for coupling mature erythrocytes in vitro. A drug (including macromolecules such as antibodies, polypeptides and nucleotides, and chemical molecules such as chemotherapeutic drugs) is coupled to glycoproteins on the surfaces of erythrocyte membranes by means of glycosidic bonds, thereby reserving the characteristics of integrity, deformation capacity, oxygen carrying capacity and long half-life of mature erythrocyte membranes, and reserving the biological activity of the drug. The method is used for treating tumors, metabolic diseases and inflammatory diseases.